Original Report

Bacteremia in adult cancer patients with apparently stable febrile neutropenia: data from a cohort of 692 consecutive episodes from a single institution


 

Background Bacteremia is associated with increased risk of complications in patients with febrile neutropenia (FN), although few clinical studies have reported outcomes in apparently stable patients (ASPs) who could be candidates for home treatment.

Objective To assess the risk factors and the impact of bacteremia in ASPs.

Methods We retrospectively analyzed 861 consecutive episodes of FN that were classified according to their presentation into 2 categories: clearly unstable patients and ASPs. We estimated the incidence of bacteremia and severe complications in ASPs. We analyzed predictors for bacteremia and the discriminatory ability of the MASCC score in this setting.

Results We classified 692 episodes as ASPs. Bacteremia occurred in 6%, major complications were noted in 7.3%, and death occurred in 1.3%. Patients with bacteremia had more complications (odds ratio [OR], 8.2), and mortality (OR, 8.2). The integration of the MASCC score and bacteremic status predicted complications with an area under the receiver operating characteristic (ROC) curve of 0.74, sensitivity of 36%, and specificity of 94%. Predictors of bacteremia were temperature ≥ 39°C/102.2°F (OR, 3), rigors (OR, 2.2), ECOG PS ≥ 2 (OR, 2.1), and advanced cancer (OR, 2.5). Two percent of patients who remained afebrile for 48 hours had positive blood cultures afterward.

Limitations A single-center, retrospective analysis, and the absence of a validation set to test the model’s discriminatory ability.

Conclusions Bacteremia is infrequent among ASPs but is associated with a high risk of complications. We identified several variables that could improve the prognostic classification of clinically stable FN.

Click on the PDF icon at the top of this introduction to read the full article.

Recommended Reading

House bill would allow corrective action plan for DEA violators
MDedge Hematology and Oncology
Radiotherapy plus chemotherapy drive risk of pancreatic cancer in HL patients
MDedge Hematology and Oncology
DEA moves hydrocodone combination products to schedule II
MDedge Hematology and Oncology
Progression-free survival, patient-reported outcomes, and the Holy Grail
MDedge Hematology and Oncology
Expanding the NCCN guidelines for distress management: a model of barriers to the use of coping resources
MDedge Hematology and Oncology
Majority of cancer patients with depression untreated; integrated collaborative care found ‘strikingly’ effective
MDedge Hematology and Oncology
Clinical judgment ‘not enough’ for decision making with elderly patients
MDedge Hematology and Oncology
VIDEO: Integrative oncology expert discusses management
MDedge Hematology and Oncology
IOM calls for pay for end-of-life planning
MDedge Hematology and Oncology
The art and science of cancer care
MDedge Hematology and Oncology